Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy

Clinical Pharmacokinetics

Volumn 53, Issue 4, 2014, Pages 373-383

  Fischer, James H ^a   Sarto, Gloria E ^b   Hardman, Jennifer ^a,c   Endres, Loraine ^d,e   Jenkins, Thomas M ^b,f   Kilpatrick, Sarah J ^d,g   Jeong, Hyunyoung ^a   Geller, Stacie ^d   Deyo, Kelly ^a   Fischer, Patricia A ^a   Rodvold, Keith A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

^e NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^f Maternal Fetal Medicine   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LABETALOL; ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; FEMALE; GESTATIONAL AGE; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; POPULATION MODEL; PRIORITY JOURNAL; PUERPERIUM; SECOND TRIMESTER PREGNANCY; STEADY STATE; THIRD TRIMESTER PREGNANCY; ADOLESCENT; HYPERTENSION, PREGNANCY-INDUCED; LONGITUDINAL STUDY; PHYSIOLOGY; PREGNANCY; PROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GESTATIONAL AGE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; LABETALOL; LONGITUDINAL STUDIES; PREGNANCY; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84898892315     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0123-0     Document Type: Article

References (47)

1. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44(10):989-1008.
2. Ganrot PO. Variation of the concentrations of some plasma proteins in normal adults, in pregnant women and in newborns. Scand J Clin Lab Invest Suppl. 1972;124:83-8.
3. Laurell CB, Rannevik G. A comparison of plasma protein changes induced by danazol, pregnancy, and estrogens. J Clin Endocrinol Metab. 1979;49(5):719-25.
4. Little B. Water and electrolyte balance during pregnancy. Anesthesiology. 1965;26:400-8.
5. Tsutsumi K, Kotegawa T, Matsuki S, et al. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. Clin Pharmacol Ther. 2001;70(2):121-5.
6. Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol. 2005;192(2):633-9.
7. Dunlop W. Serial changes in renal haemodynamics during normal human pregnancy. Br J Obstet Gynaecol. 1981;88(1):1-9.
8. Langer O, Conway DL, Berkus MD, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343(16):1134-8.
9. Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension. 2008;51(4):960-9.
10. Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology. 2002;59(2):251-5.
11. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183(1):S1-S22.
12. Seely EW, Ecker J. Clinical practice. Chronic hypertension in pregnancy. N Engl J Med. 2011;365(5):439-46.
13. Tuovinen S, Räikkönen K, Kajantie E, et al. Hypertensive disorders in pregnancy and cognitive decline in the offspring up to old age. Neurology. 2012;79(15):1578-82.
14. Andrade SE, Raebel MA, Brown J, et al. Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiol Drug Saf. 2008;17(3):240-7.
15. Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007;(1):CD002252.
16. Goa KL, Benfield P, Sorkin EM. Labetalol: A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. Drugs. 1989;37(5):583-627.
17. Nylund L, Lunell NO, Lewander R, et al. Labetalol for the treatment of hypertension in pregnancy. Pharmacokinetics and effects on the uteroplacental blood flow. Acta Obstet Gynecol Scand Suppl. 1984;118:71-3.
18. Rogers RC, Sibai BM, Whybrew WD. Labetalol pharmacokinetics in pregnancy-induced hypertension. Am J Obstet Gynecol. 1990;162(2):362-6.
19. Rubin PC, Butters L, Kelman AW, et al. Labetalol disposition and concentration-effect relationships during pregnancy. Br J Clin Pharmacol. 1983;15(4):465-70.
20. Saotome T, Minoura S, Terashi K, et al. Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. J Clin Pharmacol. 1993;33(10):979-88.
21. D'Argenio D, Schumitzky A. ADAPT II user's guide: pharmacokinetic/ pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource; 1997.
22. D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm. 1981;9(6):739-56.
23. Alton KB, Leitz F, Bariletto S, et al. High-performance liquid chromatographic assay for labetalol in human plasma using a PRP-1 column and fluorometric detection. J Chromatogr. 1984;311(2):319-28.
24. Reinard T, Jacobsen HJ. An inexpensive small volume equilibrium dialysis system for protein-ligand binding assays. Anal Biochem. 1989;176(1):157-60.
25. Jeong H, Choi S, Song JW, et al. Regulation of UDP- glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008;38(1):62-75.
26. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481-504.
27. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051-65.
28. DuBois D, DuBois EF. Clinical calorimetry: Tenth paper. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863-71.
29. Keys A, Fidanza F, Karvonen MJ, et al. Indices of relative weight and obesity. J Chronic Dis. 1972;25(6):329-43.
30. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
31. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999;59(1):19-29.
32. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28(2):171-92.
33. Donnelly R, Macphee GJ. Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol. Clin Pharmacokinet. 1991;21(2):95-109.
34. Lalonde RL, O'Rear TL, Wainer IW, et al. Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition. Clin Pharmacol Ther. 1990;48(5):509-19.
35. Carvalho TM, Cavalli ReC, Cunha SP, et al. Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients. Eur J Clin Pharmacol. 2011;67(1):55-61.
36. Johnson JA, Akers WS, Herring VL, et al. Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. Pharmacotherapy. 2000;20(6):622-8.
37. McNeil JJ, Anderson AE, Louis WJ, et al. Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. Br J Clin Pharmacol. 1979;8(Suppl 2):157S-61S.
38. Martin LE, Hopkins R, Bland R. Metabolism of labetalol by animals and man. Br J Clin Pharmacol. 1976;3(4 Suppl 3):695-710.
39. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18(4):377-90.
40. Martinez-Gomez MA, Sagrado S, Villanueva-Camanas RM, et al. Characterization of basic drug-human serum protein interactions by capillary electrophoresis. Electrophoresis. 2006;27(17):3410-9.
41. Desoye G, Schweditsch MO, Pfeiffer KP, et al. Correlation of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum. J Clin Endocrinol Metab. 1987;64(4):704-12.
42. Della Torre M, Hibbard JU, Jeong H, et al. Betamethasone in pregnancy: influence of maternal body weight and multiple gestation on pharmacokinetics. Am J Obstet Gynecol. 2010;203(3):254.e1-12.
43. Fischer JH, Sarto GE, Habibi M, et al. Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age. Antimicrob Agents Chemother. 2012;56(2):715-24.
44. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303-32.
45. Coetzee JF. Allometric or lean body mass scaling of propofol pharmacokinetics: towards simplifying parameter sets for target-controlled infusions. Clin Pharmacokinet. 2012;51(3):137-45.
46. Han PY, Duffull SB, Kirkpatrick CM, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther. 2007;82(5):505-8.
47. Brittain RT, Drew GM, Levy GP. The alpha- and beta-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues. Br J Pharmacol. 1982;77(1):105-14.